AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Atlantic Sapphire

Quarterly Report Aug 28, 2020

3543_rns_2020-08-28_adf1e3b9-7136-422a-aa34-f2c8ec130667.pdf

Quarterly Report

Open in Viewer

Opens in native device viewer

Interim Consolidated Financial Statements

S I X M O N T H S E N D E D 30 JUNE 2020

In accordance with International Financial Reporting Standards

Statement by Management and the Board of Directors

Management and the Board of Directors have today considered and approved the interim consolidated financial statements of Atlantic Sapphire ASA (collectively, the "Group") for the period 1 January 2020 to 30 June 2020. The interim report, which has not been audited or reviewed by the Group's independent auditors, has been prepared in accordance with IAS 34 Interim Financial Reporting as adopted by the EU disclosure requirements for listed companies. In our opinion, the accounting policies used are appropriate, and the interim report gives a true and fair view of the Group's financial position at 30 June 2020, as well as the

results of the Group's activities and cash flows for the period 1 January 2020 to 30 June 2020. In our opinion, Management's review provides a true and fair presentation of developments, results for the period, and overall financial position of the Group's operations in addition to a description of the most significant risks and elements of uncertainty facing the Group. Over and above the disclosures in the interim report, no changes in the Group's most significant risks and uncertainties have occurred relative to the disclosures in the annual report for 2019.

Vikebukt, 27 August 2020

Johan E. Andreassen Chairman

André Skarbø Director

Tone Bjørnov Director

Ellen Marie Sætre Director

Runar Vatne Director

Alexander Reus Director

Patrice Flanagan Director

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS SIX MONTHS ENDED 30 JUNE 2020, 30 JUNE 2019, AND YEAR ENDED 31 DECEMBER 2019

Unaudited (USD 1,000) Note 30 June 2020 30 June 2019 31 Dec 2019
Revenue 2,502 2,021 5,540
Expenses
Cost of materials 5,328 2,187 6,582
Fair value adjustment on biological assets 3 11,216 (704) (458)
Salary and personnel costs 2,831 1,643 3,795
Other operating expenses 5,132 3,423 6,803
Depreciation and amortization 4 1,289 1,039 2,286
Total expenses 25,796 7,588 19,008
Operating loss (23,294) (5,567) (13,468)
Financial income 104 183 3,640
Financial expense (8,467) (4,062) (3,338)
Other income, net 83 3 14
Loss before income tax benefit (31,574) (9,443) (13,152)
Income tax benefit - - -
Net loss (31,574) (9,443) (13,152)
Earnings per share:
Basic earnings per share
Diluted earnings per share
(0.46)
(0.46)
(0.15)
(0.15)
(0.19)
(0.19)
Unaudited (USD 1,000) Note 30 June 2020 30 June 2019 31 Dec 2019
Net loss (31,574) (9,443) (13,152)
Exchange difference on translation of foreign operations 126 7,884 (917)
Total comprehensive loss (31,448) (1,559) (14,069)

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION 30 JUNE 2020, 30 JUNE 2019, AND 31 DECEMBER 2019

Unaudited (USD 1,000) Note 30 June 2020 30 June 2019 31 Dec 2019
ASSETS
Non-current assets
Property, plant, and equipment, net
Right of use asset 4 241,147 170,185 209,616
Restricted cash (long-term) 446 - 355
Security deposits - 15,000 15,000
Patents 821 264 726
Other investments -
11
174
11
-
11
Trade and other receivables (long-term) 81 275 118
Total non-current assets 242,506 185,909 225,826
Current assets
Prepaid and other current assets 649 1,215 1,933
Inventories 3,337 155 3,302
Biological assets 3 8,070 7,386 11,275
Trade and other receivables (short-term) 612 1,419 1,069
Restricted cash (short-term) 332 309 324
Cash 10,815 65,706 9,147
Total current assets 23,815 76,190 27,050
TOTAL ASSETS 266,321 262,099 252,876
EQUITY AND LIABILITIES
Equity
Share capital
Share premium 6
6
818
236,851
818
236,819
818
236,819
Employee stock options 6 1,503 983 1,060
Accumulated deficit (59,006) (27,782) (27,432)
Accumulated other comprehensive (loss) gain (2,460) 5,298 (2,586)
Total equity 177,706 216,136 208,679
Non-current liabilities
Borrowings (long-term) 5 71,116 27,135 27,319
Lease liability (long-term) 487 - 379
Total non-current liabilities 71,603 27,135 27,698
Current liabilities
Borrowings (short-term) 5 - 67 79
Trade and other payables 17,012 18,761 16,420
Total current liabilities 17,012 18,828 16,499
Total liabilities 88,615 45,963 44,197
TOTAL EQUITY AND LIABILITIES 266,321 262,099 252,876

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY SIX MONTHS ENDED 30 JUNE 2020, 30 JUNE 2019, AND YEAR ENDED 31 DECEMBER 2019

Unaudited (USD 1,000) Share
capital
Share
premium
Employee
stock options
Accumulated
deficit
Accumulated
other
comprehensive loss
Total
equity
Balance at 31 December 2018 720 151,764 904 (14,280) (1,669) 137,439
Contributions
Net loss
Foreign currency translation adjustments
98
-
-
85,055
-
-
156
-
-
-
(13,152)
-
-
-
(917)
85,309
(13,152)
(917)
Balance at 31 December 2019 818 236,819 1,060 (27,432) (2,586) 208,679
Contributions
Net loss
Foreign currency translation adjustments
-
-
-
32
-
-
443
-
-
-
(31,574)
-
-
-
126
475
(31,574)
126
Balance at 30 June 2020 818 236,851 1,503 (59,006) (2,460) 177,706

CONSOLIDATED STATEMENTS OF CASH FLOWS SIX MONTHS ENDED 30 JUNE 2020, 30 JUNE 2019, AND YEAR ENDED 31 DECEMBER 2019

Unaudited (USD 1,000) Note 30 June 2020 30 June 2019 31 Dec 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss (31,574) (9,443) (13,152)
Adjustments to reconcile net loss to net cash
used in operating activities
Depreciation and amortization 4 1,289 1,039 2,286
Fair value adjustment on biological assets 3 11,216 (704) (458)
Loss from disposition of other assets 31 - 25
Net interest received and paid 8,349 1,730 526
Non-cash employee stock options 6 443 411 156
Net foreign currency exchange rate differences 359 (165) (153)
Changes in operating assets and liabilities
Trade and other receivables 497 (894) (90)
Inventories and biological assets, at cost 3 (8,026) (3,467) (10,793)
Prepaid and other current assets 1,288 1,025 41
Security deposits (95) (264) (726)
Trade and other payables (2,439) (467) 3,776
Interest received 14 - 100
Net cash used in operating activities (18,648) (11,199) (18,462)
CASH FLOWS FROM INVESTING ACTIVITIES
Payments towards property, plant, and equipment 4 (29,676) (39,032) (86,790)
Right of use asset (90) - -
Net cash used in investing activities (29,766) (39,032) (86,790)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from borrowings 5 95,156 39,544 42,595
Payments towards borrowings 5 (51,438) (13,621) (16,288)
Restricted cash on borrowings 14,991 (15,309) (15,005)
Lease liability 107 - -
Proceeds from issuance of capital 32 87,683 85,153
Interest paid (8,363) (1,543) (626)
Net cash provided by financing activities 50,485 96,754 95,829
Net increase (decrease) in cash 2,071 46,523 (9,423)
Cash at beginning of period 9,147 19,018 18,699
Effects of exchange rate on cash (403) 165 (129)
Cash at end of period 10,815 65,706 9,147

NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

General Information

Atlantic Sapphire ASA ("ASA") is a Norwegian company headquartered at Vikebukt, Norway and listed on the Oslo Stock Exchange with the ticker symbol "ASA". ASA owns the following subsidiaries (collectively, the "Group"):

  • Atlantic Sapphire Denmark A/S ("ASDK", registered in Hvide Sande, Denmark)
  • Atlantic Sapphire USA LLC ("ASUS", registered in Miami, Florida, USA)
  • AS Purchasing, LLC ("ASP", registered in Miami, Florida, USA)
  • S.F. Development, L.L.C. ("ASSF", registered in Miami, Florida, USA)
  • Atlantic Sapphire IP, LLC ("ASIP", registered in Miami, Florida, USA)

The Group's interim consolidated statements for the six months ended 30 June 2020 were prepared in accordance with IAS 34 Interim Financial Reporting under International Financial Reporting Standards ("IFRS") as adopted by the European Union ("EU").

This interim financial report does not include all the notes of the type normally included in an annual financial report. Accordingly, this interim financial report is to be read in conjunction with the Group's Annual Report for the year ended 31 December 2019 and any public announcements made by Atlantic Sapphire ASA during the interim reporting period. The interim report is unaudited and is presented in United States dollars ("USD").

Basis for Preparation of the Accounts

The Group's accounting policies adopted are consistent with those applied in the Group's 2019 Annual Report as published on the Oslo Stock Exchange on 26 March 2020. No new standards under IFRS have been adopted by the Group in 2020.

Reclassification

Certain amounts in the Group's 2019 consolidated financial statements have been reclassified to conform to the 2020 presentation. The reclassifications have no effect on the Group's consolidated financial position or previously reported results of consolidated operations.

NOTE 2 – SEGMENTS

The Group has two strategic divisions, which represent its reportable segments. The Group's executive management reviews the internal management reports of each division. As of 30 June 2020, the Group's reportable segments consisted of the following:

Fish Farming (Denmark)

The Group owns and operates a proprietary Bluehouse land-based salmon farm in Hvide Sande, Denmark through ASDK. Principal operations consist of the production and sale of salmon.

Fish Farming (USA)

The Group owns and operates a proprietary Bluehouse land-based salmon farm in Homestead, Florida, USA through ASUS (the "Miami Bluehouse"). The Miami Bluehouse is currently under Phase 1 of its construction build out and is projected to reach approximately 10,000 tons annualized HOG1 production in 2021.

The Group's segment information consisted of the following:

Six months ended 30 June 2020 Fish farming
Unaudited (USD 1,000) Denmark USA Other and
eliminations
Consolidated
Revenue from sale of salmon 2,812 172 (482) 2,502
EBITDA (6,243) (14,136) (1,543) (21,922)
Pre-tax loss (8,245) (22,559) (770) (31,574)
Total assets 41,256 227,991 (2,926) 266,321
Total liabilities 37,551 85,350 (34,286) 88,615
Depreciation and amortization 1,215 74 - 1,289
Capital expenditures 1,474 31,284 - 32,758

Six months ended 30 June 2019 Fish farming

Unaudited (USD 1,000) Denmark USA Other and
eliminations
Consolidated
Revenue from sale of salmon 2,021 - - 2,021
EBITDA (886) (2,793) (846) (4,525)
Pre-tax loss (2,538) (4,501) (2,404) (9,443)
Total assets 42,651 172,062 47,386 262,099
Total liabilities 35,037 43,928 (33,002) 45,963
Depreciation and amortization 342 27 670 1,039
Capital expenditures 9,334 32,771 2,994 45,099

1 HOG – "Head-On-Gutted" fish, a term used industry-wide, is approximately 83% of live weight fish.

ATLANTIC SAPPHIRE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

Year ended 31 December 2019 Fish farming
Unaudited (USD 1,000) Denmark USA Other and
eliminations
Consolidated
Revenue from sale of salmon 6,413 - (873) 5,540
EBITDA (3,147) (7,124) (897) (11,168)
Pre-tax loss (6,957) (7,730) 1,535 (13,152)
Total assets 47,319 204,387 1,170 252,876
Total liabilities 35,235 41,187 (32,225) 44,197
Depreciation and amortization 2,206 80 - 2,286
Capital expenditures 7,001 79,156 - 86,157

Significantly all the Group's revenue consisted of the sale of salmon, and the Group's disaggregation of revenue with customers consisted of the following:

Unaudited (USD 1,000) 30 June 2020 30 June 2019 31 Dec 2019
Revenue from external customers in:
Denmark 815 397 2,390
United States 639 151 1,834
Europe 1,048 1,473 1,316
Total revenue from external customers 2,502 2,021 5,540

The Group's concentration of revenue consisted of the following:

Unaudited (USD 1,000) 30 June 2020 30 June 2019 31 Dec 2019
Sales per customer:
Customer A 639 1,196 1,834
Customer B 619 353 1,433
Customer C 196 151 957
Customer D 382 159 607
Customer E 544 - 348
Other customers 122 162 361
Total revenue from significant customers 2,502 2,021 5,540

NOTE 3 – BIOLOGICAL ASSETS

Fair Value Measurement of Biological Assets

Under the provisions of IAS 41, the fair value of the Group's biological assets is calculated based on the market price for the relevant fish quality and size on the reporting period date. As the biomass input is mostly unobservable, biomass valuation is categorized at Level 3 in the fair value hierarchy under IFRS 13. The estimated market price in each market is normally derived from the development in recent market prices. Quoted forward prices from Fish Pool, a third-party, are used in the estimation to improve reliability and comparability of the price estimation.

The valuation model for the Group's biological assets calculates the net present value of the expected cash flow from harvested biomass based on the actual number of fish as a starting point. The time to market for live fish is based on a growth table for each generation of fish. The Group considers a live fish weight of 4.5 kg to be the target harvest weight with an expected growth period of 21 months. Expected mortality rates are used to estimate the expected volume of biomass that will reach optimal harvest weight. Fish Pool forward prices are used to determine the expected cash inflows at the time of harvest. Future cash flows are discounted at a monthly rate of 10%. Observable market prices are used where available.

The Group's biological assets consisted of the following:

Unaudited (USD 1,000) 30 June 2020 30 June 2019 31 Dec 2019
Cost of biological assets
Accumulated fair value adjustments
18,213
(10,143)
6,885
501
10,864
411
Total biological assets 8,070 7,386 11,275

The following represents a reconciliation of changes in the carrying amount of the Group's biological assets:

Unaudited (USD 1,000) 30 June 2020 30 June 2019 31 Dec 2019
Biological assets at beginning of period 11,275 3,283 3,283
Gain or loss arising from changes in fair value less costs to sell (11,216) 704 458
Increases due to production and purchases 13,059 5,327 13,865
Decreases due to harvest (2,428) (1,661) (5,978)
Decreases due to mortality (2,576) (257) (297)
Net exchange rate differences (44) (10) (56)
Biological assets at end of period 8,070 7,386 11,275

The Group's physical volumes of biological assets consisted of the following:

Unaudited (USD 1,000) 30 June 2020 30 June 2019 31 Dec 2019
Live weight of biomass (in tons)
Non-harvestable fish 354 96 354
Harvestable fish 1,666 1,008 821
Total live weight of biomass (in tons) 2,020 1,104 1,175
Number of fish (in thousands)
Non-harvestable fish 3,490 2,901 4,114
Harvestable fish 1,176 292 300
Total number of fish (in thousands) 4,666 3,193 4,414
Volume of fish harvested during the year (tons gutted weight) 353 288 1,022

NOTE 4 – PROPERTY, PLANT, AND EQUIPMENT

Property, plant, and equipment consisted of the following:

Unaudited (USD 1,000) Land Buildings Production,
plant, and
machinery
Equipment
and other
movables
Software Assets under
construction
Total
At 1 January 2020
Cost 8,714 15,218 22,840 1,019 180 167,070 215,041
Less: accumulated depreciation - (1,317) (3,746) (362) - - (5,425)
Net book amount 8,714 13,901 19,094 657 180 167,070 209,616
Six months ended 30 June 2020
Opening net book amount 8,714 13,901 19,094 657 180 167,070 209,616
Additions - - - 34 105 32,619 32,758
Reclassifications - 881 520 73 - (1,474) -
Disposals - - - - - - -
Depreciation charge - (395) (782) (89) (30) - (1,296)
Reversed depreciation - - - - - - -
Net exchange rate differences - 63 70 3 (2) (65) 69
Closing net book amount 8,714 14,450 18,902 678 253 198,150 241,147
At 30 June 2020
Cost 8,714 16,162 23,430 1,129 283 198,150 247,868
Less: accumulated depreciation - (1,712) (4,528) (451) (30) - (6,721)
Net book amount 8,714 14,450 18,902 678 253 198,150 241,147
Unaudited (USD 1,000) Land Buildings Production,
plant, and
machinery
Equipment
and other
movables
Software Assets under
construction
Total
At 1 January 2019
Cost 3,691 10,251 21,677 702 - 93,272 129,593
Less: accumulated depreciation - (715) (2,368) (210) - - (3,293)
Net book amount 3,691 9,536 19,309 492 - 93,272 126,300
Year ended 31 December 2019
Opening net book amount 3,691 9,536 19,309 492 - 93,272 126,300
Additions 5,023 - - 323 180 80,631 86,157
Reclassifications - 5,176 1,624 14 - (6,814) -
Disposals - (30) (83) (16) - (12) (141)
Depreciation charge - (631) (1,475) (161) - - (2,267)
Reversed depreciation - 29 97 9 - - 135
Net exchange rate differences - (179) (378) (4) - (7) (568)
Closing net book amount 8,714 13,901 19,094 657 180 167,070 209,616
At 31 December 2019
Cost 8,714 15,218 22,840 1,019 180 167,070 215,041
Less: accumulated depreciation - (1,317) (3,746) (362) - - (5,425)
Net book amount 8,714 13,901 19,094 657 180 167,070 209,616

NOTE 5 – BORROWINGS

On 21 April 2020, the Group amended the 2019 DNB Credit Facility (the "2020 DNB Credit Facility") with DNB ASA which, among other conditions, increased the aggregate amount of USD 86m to USD 210m. Under the amended terms, the USA Term Loan was increased from USD 54m to USD 70m, the USA RCF was increased from USD 11m to USD 26m, and the DK RCF remained unchanged at USD 4m. The USD 17m bridge facility under the 2019 DNB Credit Facility was removed, and a delayed draw term loan of USD 110m was extended to the Group towards Phase 2 construction.

The Group's borrowings consisted of the following:

Unaudited (USD 1,000) 30 June 2020 30 June 2019 31 Dec 2019
ASUS has a USD 70m term loan with DNB (the "USA Term Loan"). The USA
Term Loan bears an amended interest rate of LIBOR plus 4.5% and matures
on 21 October 2021. USD 70m was drawn on the USA Term Loan as of
30 June 2020.
69,960 27,202 27,398
ASUS has a three-year USD 26m revolving credit facility commitment with
DNB (the "USA RCF"). The USA RCF will finance ASUS' working capital requi
rements, and no funds have been drawn as of 30 June 2020.
- - -
ASDK has a three-year USD 4m revolving credit facility commitment with DNB
(the "DK RCF"). The DK RCF will finance ASDK's working capital requirements,
and no funds have been drawn as of 30 June 2020.
- - -
ASUS had a USD 17m bridge facility with DNB. During the year ended 31
December 2019, USD 12m was drawn and subsequently repaid following the
completion of the Group's 8 May 2019 equity raise.
- - -
ASUS has a two-year loan payable (the "PPP Loan") to PNC Bank, National
Association ("PNC"). The PPP Loan was obtained on April 2020 under the
Paycheck Protection Program (the "Program") as part of the Coronavirus
Aid, Relief, and Economic Security ("CARES") Act passed in March 2020. The
PPP Loan bears an interest rate of 1% and matures on April 2022. Payment
is deferred for the first six months at which point an the outstanding principal
of the PPP Loan that is not unforgiven under the Program is payable to the
maturity date.
1,156 - -
Total borrowings
Less: short-term portion of borrowings
71,116
-
27,202
(67)
27,398
(79)
Long-term portion of borrowings 71,116 27,135 27,319

During the year ended 31 December 2019, ASUS incurred USD 3.1m in debt issuance costs in connection to the USA Term Loan under the 2019 DNB Credit Facility. Total unamortized debt issuance costs as of 31 December 2019 were USD 2.6m and were presented against its respective portion of short-term and long-term borrowings.

At 21 April 2020, total unamortized debt issuance costs presented against borrowings were USD 2.4m. Upon amending the USA Term Loan under the 2020 DNB Credit Facility, ASUS incurred USD 5.8m in new debt issuance costs. In accordance with IFRS 9 Financial Instruments, the previously unamortized debt issuance costs of USD 2.4m and USD 5.8m in new debt issuance costs were recognized as part of finance expense in the consolidated statements of operations.

NOTE 6 – SHARE CAPITAL AND SHAREHOLDERS

The total number of shares issued and outstanding consisted of the following:

30 June 2020
Number of shares % of shares
Alsco AS 9,459,849 13.27%
Regents of the University of Michigan 4,360,478 6.12%
Vatne Equity AS 4,050,000 5.68%
Skagen Kon-Tiki Verdipapirfond 3,877,995 5.44%
State Street Bank and Trust Comp 2,656,208 3.73%
Brown Brothers Harriman & Co. 2,275,092 3.19%
Morgan Stanley & Co. Int. Plc. 2,185,933 3.07%
Citibank, N.A. 2,063,786 2.90%
U.S. Bank National Association 2,030,227 2.85%
Pershing LLC 1,342,019 1.88%
Joh Johannson Eiendom AS 1,340,926 1.88%
Verdipapirfondet Norge Selektiv 1,234,611 1.73%
Lani Invest AS 1,112,997 1.56%
JEA Invest AS 1,072,270 1.50%
UBS Switzerland AG 1,032,351 1.45%
Blue Future Holding AS 1,021,621 1.43%
Norron Sicav - Active 935,861 1.31%
Goldman Sachs & Co. LLC 876,653 1.23%
Verdipapirfondet DNB Norge 842,222 1.18%
Norron Sicav - Target 806,200 1.13%
Total number of shares attributed to the 20 largest shareholders 44,577,299 62.54%
Total number of shares attributed to other shareholders 26,698,801 37.46%
Total number of shares issued and outstanding 71,276,100 100.00%

On 4 May 2020, Atlantic Sapphire AS converted from a private company to Atlantic Sapphire ASA, a public company. On 5 May 2020, Atlantic Sapphire ASA listed on the Oslo Stock Exchange under the ticker symbol "ASA".

NOTE 7 – SIGNIFICANT AND SUBSEQUENT EVENTS

Recent developments with respect to the COVID-19-virus (the "Coronavirus"), an infectious virus closely related to the SARS virus, has impacted supply chain and construction operations of the Group. In addition, Norwegian salmon prices have experienced a downward trend, pressured down by various factors including concerns over lower global exports due to the Coronavirus. Ultimately, the consequences and timeline of the Coronavirus are still unclear and the overall effect on the business is uncertain.

On 28 July 2020, ASUS initiated an emergency harvest from one of its partially commissioned grow-out systems. As a result of the event, approximately 200,000 salmon with a total weight of approximately 400 tons (HOG) were harvested. Other grow-out systems of the Miami Bluehouse were unaffected. The exact chain of events is still under investigation and preliminary findings do not indicate intoxication or disease as the cause of the event. Rather, the Group believes disruptive construction work close to the operating environment acutely stressed the fish through loud sounds and severe vibrations. Recent challenges of delayed construction and commissioning of critical components, in part because of the Coronavirus pandemic impact, have resulted in increased operational risk and limit the tools the Group has to deal with non-conformities. The Group believes that the event would have likely been mitigated if the permanent fish movement system would have been fully commissioned. The Group is still assessing the complete financial impact of the event including insurance proceeds.

www.atlanticsapphire.com

Talk to a Data Expert

Have a question? We'll get back to you promptly.